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MicroRNAs are a class of small, endogenous, non-coding RNAs that function as post-transcriptional
regulators. In this study, we found that miR-181b promoted cell proliferation and inhibited cell
apoptosis in cervical cancer cells. And we validated a new miR-181b target gene, adenylyl cyclase
9 (AC9). miR-181b restricted cAMP production by post-transcriptionally downregulating AC9
expression. Phenotypic experiments indicated that miR-181b and AC9 exerted opposite effects on
cell proliferation and apoptosis.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Cyclic AMP (cAMP) is produced from ATP by 10 different iso-MicroRNAs are endogenous RNAs of approximately 22 nt in
length that base-pair with the mRNAs of protein-coding genes
and direct the post-transcriptional repression of these mRNAs
[1]. miR-181b belongs to the miR-181 family and plays important
regulatory roles in the cell cycle and differentiation [2–4]. miR-
181b also plays diverse roles in different cancer cell lines [5,6]. Fur-
thermore, miR-181b may stimulate HeLa cell growth and inhibit
cell death [7].
Cervical cancer is a commoncancer in females.Although the intro-
ductionof cervical cytological scanning and improved early diagnosis
have signiﬁcantly decreased the morbidity and mortality of this dis-
ease in thepast four decades [8,9], it remains a problem indeveloping
countries due to poor access to medical services. The roles of some
microRNAs in cervical cancer cells have recently been discovered.
miR-214 negatively regulates HeLa cell proliferation by targeting
the MEK3 and JNK1 mRNAs [10]. microRNA-19a and -19b regulate
cervical cancer cell proliferation and invasion by targeting CUL5 [11].forms of AC in mammals, including the membrane-bound AC1-
AC9 isoforms and a soluble AC isoform, and can be degraded into
50-AMP by phosphodiesterases [12–14]. As a second messenger,
cAMP can either stimulate or inhibit apoptosis [15–18]. In HeLa
cells, cAMP inhibits cell growth and promotes apoptosis [19], and
cAMP analogs could potentially be used as anti-cancer drugs
[20,21]. Downregulation of AC9 by miR-142-3p restricts cAMP pro-
duction and promotes cell proliferation [22]. In our research, we
found that miR-181b promoted the growth of cervical cancer cells
and inhibited their apoptosis by targeting the adenylyl cyclase 9
(AC9) gene and reducing the levels of cellular cAMP.
2. Materials and methods
2.1. Cervical cancer tissues, RNA preparation and quantitative RT-PCR
analysis
Fifteen pairs of cervical cancer tissue and the adjacent normal
tissue were obtained at the Cancer Center of Sun Yat-sen Univer-
sity of Medical Science in accordance with the ethical standards
of the institutional committee.
Large and small RNAs from the tissues were isolated with the
mir-Vana miRNA Isolation Kit (Ambion, Austin, TX, USA) according
to the manufacturer’s protocol. Five micrograms of an RNA sample
was used in a reverse transcriptase reaction (Promega, Madison
WI); the resulting cDNA was used for the ampliﬁcation of AC9
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detect the relative transcript levels of miR-181b and AC9. PCR
was performed under the following conditions: 94 C for 4 min fol-
lowed by 40 cycles of 94 C for 1 min, 56 C for 1 min and 72 C for
1 min. The relative expression levels of the genes of interest were
calculated by the 2DDCt method. All primers were synthesized
by AuGCT Inc. (Beijing, China).
2.2. miRNA target prediction
The miRNA targets were predicted by the computer-aided algo-
rithms of PicTar and TargetScan Release 5.1.
2.3. Plasmid construction and oligonucleotides
We constructed the following vectors: pcDNA3/pri-miR-
181b, pcDNA3/EGFP0-AC9-30UTR#1, pcDNA3/EGFP-AC9-30UTR#2,
pcDNA3/EGFP-AC9-30UTR#1 mutant, pcDNA3/EGFP-AC9-30UTR#2
mutant, pSilencer/shRNA-AC9, and pcDNA3/HA-AC9. ASO-miR-
181b (ACCCACCGACAGCAGCAAUGAAUGUU) and ASO-NC were
obtained from GenePharma, Shanghai, China.
2.4. Cell lines and transfection
HeLa and C-33A cells were maintained in RPMI 1640 (GIBCO)
with 10% heat-inactivated fetal bovine serum, 100 IU/ml penicillin,
and 0.1 mg/ml streptomycin in a humidiﬁed 5% (v/v) atmosphere
of CO2 at 37 C. Transfection was performed using Lipofectamine™
2000 Reagent following the manufacturer’s protocol (Invitrogen,
Carlsbad, CA).
2.5. Fluorescent reporter assay
HeLa and C-33A cells were transfected with 0.2 lg of EGFP re-
porter vector under control of a wild-type or mutant AC9 30UTR
in 48-well plates. The cells were cotransfected with 20 pmol of
ASO against miR-181b or 0.2 lg of pcDNA3/pri-miR-181b per well.
The assay was normalized with 0.05 lg of the red ﬂuorescent pro-
tein expression vector pDsRed2-N1 (Clontech, Mountain View, CA,
USA). At 48 h after transfection, the cells were lysed with RIPA lysis
buffer (0.15 M NaCl, 0.05 M Tris/HCl pH 7.2, 1% Triton X-100, 0.1%
SDS). The ﬂuorescence intensities of EGFP and red ﬂuorescent pro-
tein were detected with an F-4500 Fluorescence Spectrophotome-
ter (Hitachi, Tokyo, Japan).
2.6. Western blot
The cells were incubated for 48 h after transfection. Cultured
cells were lysed with RIPA lysis buffer. The lysates were collected
and cleared by centrifugation, and the protein concentration was
determined. The whole cell lysates (50 lg of total protein) were
separated by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, and the proteins were transferred onto nitrocellulose
membranes. The membranes were incubated with an antibody
against AC9 or glyceraldehyde-3-phosphate dehydrogenase (GAP-
DH) overnight at 4 C. The membranes were then incubated with
goat anti-rabbit peroxidase-conjugated secondary antibody. Pro-
tein expression was assessed by enhanced chemiluminescence
and exposure to chemiluminescent detection ﬁlm. Antibodies were
purchased from Tianjin Saier Biotechnology. Each assay was per-
formed in triplicate.
2.7. MTT assay
HeLa and C-33A cells were seeded in a 96-well plate at a density
of 5000 (HeLa) or 8000 (C-33A) cells per well one day beforetransfection. The cells were transfected with 0.15 lg of pri-miR-
181b or the control vector per well. At 24 h after transfection,
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay was used to determine cell viability at 48, 72, and 96 h
after transfection. The absorbance at 570 nm was measured using
an IQuant Universal Microplate Spectrophotometer (BioTek,
Winooski, VT).
2.8. Colony formation assay
Cell growth activity was determined for HeLa and C-33A cells
by colony formation analysis. At 24 h after transfection, the cells
were harvested and seeded at a density of 200 (HeLa) or 300 (C-
33A) cells per well in 12-well plates. The plates were incubated
at 37 C and 5% CO2 in a humidiﬁed incubator for 2 weeks.
During colony growth, the culture medium was replaced every
3 days.
2.9. TUNEL assay
The terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL) assay was performed using the In-Situ Cell
Death Detection Kit (Roche Diagnostics Corporation, Indianapolis,
IN, USA). Cells were transfected with 100 nM ASO or 5 ng/lL of
each plasmid as described above. At 24 h after transfection, the
cells were trypsinized, counted, and seeded at a density of 4000
cells per well in 14-well slides. The cells were then treated with
2.5 plasma peak concentration (ppc) paclitaxel for 6 h and ﬁxed
with paraformaldehyde (4% in PBS, pH 7.4). Nuclei were stained
with 4,6-diamidino-2-phenylindole (DAPI, Dojindo Molecular
Technologies, Inc., Japan). Fluorescence images were obtained
using a Digital Sight DS-U1 scanning microscope (Nikon, Tokyo,
Japan).
2.10. cAMP assay
HeLa and C-33A cells were incubated to detect cAMP levels. At
24 h after transfection, the cAMP concentration was measured
using a cAMP immunoassay kit (ParameterTM cAMP immunoassay
kit, R&D Systems, UK).
2.11. Flowcytometry assay
At 24 h after transfection, HeLa cells were used to perform the
assay by following manufacturer’s protocol (Pharmingen Annex-
inV, BD Systems). The data were analyzed by using the software
provided by the company.
2.12. Statistical analysis
Data are presented as the mean ± standard deviation (S.D.). Stu-
dent’s t-test was used to evaluate signiﬁcant differences, with
P < 0.05 considered statistically signiﬁcant.
3. Results
3.1. miR-181b stimulates the proliferation of cervical cancer cells
To determine the effects of miR-181b in vitro, the overexpres-
sion plasmid pcDNA3/pri-miR-181b (pri-miR-181b) or the
antisense oligonucleotide of miR-181b (ASO-miR-181b) were
transfected into two human cervical cancer cell lines (HeLa and
C-33A cells). The expression of miR-181b in cells with pri-miR-
181b was increased, but its expression in cells with ASO-miR-
181b was decreased (Fig. 1A). Next, we performed assays to
examine the effect of miR-181b on HeLa and C-33A cells. MTT
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whereas ASO-miR-181b reduced cell viability by 25% (Fig. 1B).
The results of ﬂowcytometry assays showed that miR-181b can in-
hibit cell apoptosis (Fig. 1C). The TUNEL assays indicated similar
results in HeLa (S1). To detect the effect of miR-181b on theFig. 1. Overexpression of miR-181b stimulates the proliferation of cervical cancer cells. (
181b) or ASO-miR-181b. The expression levels of miR-181b in cells were determined 24
Cell viability was determined 48, 72, and 96 h post-transfection by the MTT assay. (C
ﬂowcytometry assay results were shown. (D) Experiments were carried out as described
2 weeks post-transfection (P < 0.05).long-term growth of HeLa and C-33A cells, a plate-based colony
formation assay was performed. Compared with the control group,
the colony numbers of the two cell lines treated with pri-miR-181b
increased approximately 1.5- to 2-fold, whereas those of the cell
lines with ASO-miR-181b were reduced by 70% (Fig. 1D). TheseA) The HeLa and C-33A cells were transfected with pcDNA3/pri-miR-181b (pri-miR-
h post-transfection by qRT-PCR. (B) Experiments were carried out as described in A.
) Experiments were carried out as described in A. The representative pictures of
in A. The cell growth capacity in vitro was assessed by the colony formation assay
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duces apoptosis in cervical cancer cells.
3.2. The AC9 carries a 3’UTR with a miR-181b binding site and its
expression is negatively regulated by miR-181b
We used the Targetscan and PicTar bioinformatic methods to
predict hundreds of potential miR-181b target genes. Among these
targets, the 30UTR of the AC9 transcript has two potential comple-
mentary miR-181b binding sites. In addition, AC9 belongs to the
adenylate cyclase family and synthesizes the second messenger
cAMP [23]; cAMP is able to induce growth arrest and apoptosis
in diverse cancer cell lines, including cervical cancer cells [24–
27]. Thus, we have chosen the AC9 gene as a target of miR-181b
for further study.
Two miR-181b binding sites were predicted in the 30UTR of
the AC9 mRNA at nucleotides 1898–1904 (#1) and 2554–2560
(#2). We constructed EGFP reporter vectors with either the
wild-type AC9 30UTR which could be targeted by miR-181b
through its binding or the UTR with a mutation to prevent
miR-181b from binding (Fig. 2A). Compared with the control
group of EGFP without AC9 30UTR, we found that the ﬂuores-
cence intensity of EGFP with 30UTR#2 decreased by 50% in HeLa
cells and 30% in C-33A cells, while that of EGFP with UTR#2
mutant showed no apparent change. Unlike that with 30UTR#2,
the EGFP with 30UTR#1 showed no visible difference with the
control group in ﬂuorescence intensity (Fig. 2B). Pri-miR-181b
or ASO-miR-181b was cotransfected with reporter vector intoFig. 2. AC9 is a direct target of miR-181b. (A) The predicted and the mutated miR-181b
expression of miR-181b on the expression of a reporter gene with the 30UTR of AC9 mRN
HeLa and C-33A cells were transfected with the wild-type or the mutated pcDNA3/EG
incubated for 48 h after transfection. The EGFP expression was measured by ﬂuorescen
mutated pcDNA3/EGFP-AC9 30UTR#2 reporter vector along with pri-miR-181b or ASO-mi
ﬂuorescence intensity. (E and F) HeLa and C-33A cells were transfected with pri-miR-181b
blot, respectively. (G and H) The relative expression levels of miR-181b and AC9 in the 15
qRT-PCR; U6 or b-actin was used for normalization (P < 0.05).HeLa and C-33A cells respectively. As shown in Fig. 2D, the ﬂuo-
rescence intensity of EGFP with 30UTR#2 decreased approxi-
mately 70% in cells with the pri-miR-181b or increased
approximately 6-fold in that with ASO-miR-181b. In contrast,
the ﬂuorescence intensity of EGFP with 30UTR#1, 30UTR#1mut
and 30UTR#2mut showed no apparent change when pri-miR-
181b or ASO-miR-181b was cotransfected (Fig. 2C and D). On
consider of all the results above, we suggested that miR-181b
mainly binds to 30UTR#2 to perform its function.
Because the 30UTR#2 of AC9 can be targeted by miR-181b, it is
interesting to know whether the expression of AC9 is affected by
the targeting. The level of AC9 mRNA and the expression of the
protein were measured by qRT-PCR and Western blot analysis,
respectively. We found that the levels of AC9 mRNA decreased
by approximately 75% in cells overexpressing miR-181b compared
with the control group, whereas AC9 mRNA levels increased 6- to
8-fold when the microRNAs were blocked by ASO-miR-181b in
cells (Fig. 2E). Similarly, overexpression or knockdown of miR-
181b led to decreased or enhanced AC9 protein expression, respec-
tively (Fig. 2F).
Moreover, the levels of miR-181b and AC9 mRNA were also
measured in 15 pairs of cervical cancer and their adjacent normal
tissues using qRT-PCR. Compared with the matched normal tissues,
we found that the level of miR-181b was higher (Fig. 2G) while that
of AC9 mRNA was lower (Fig. 2H) in tumor tissues. These results
indicate that miR-181b can repress the expression of AC9 in cervi-
cal cancer cells by promoting the degradation of its mRNA through
binding of its 30UTR#2.binding sites in the 30UTR of AC9 mRNA are shown. (B) The effect of endogenous
A or its mutated form. EGFP expression was measured by ﬂuorescence intensity. (C)
FP-AC9 30UTR#1 reporter vector along with pri-miR-181b or ASO-miR-181b and
ce intensity. (D) HeLa and C-33A cells were transfected with the wild-type or the
R-181b and incubated for 48 h after transfection. EGFP expression was measured by
or ASO-miR-181b. AC9 mRNA and protein were measured by qRT-PCR andWestern
pairs of cervical cancer tissues and matched normal tissues were determined with
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AC9 synthesizes cAMP; therefore, we tested whether miR-181b
could reduce the cAMP concentration in HeLa and C-33A cells.
Overexpression of miR-181b resulted in approximately 50% de-
creased cAMP concentration, and inhibition of miR-181b resulted
in a 1.5-fold increase in cAMP concentration (Fig. 3A). The AC9
mRNA and protein levels, as well as cAMP production, were af-
fected by changes in miR-181b levels, indicating that miR-181b
negatively regulates the expression of AC9 and thus reduces cAMP
production.
To conﬁrm that miR-181b represses the cellular function of
AC9, we constructed the pSilencer/shR-AC9 plasmid to knockdown
the expression of AC9. qRT-PCR and Western blot analysis indi-
cated that the shR-AC9 effectively reduced the AC9 mRNA and pro-
tein levels by 50% and 75%, respectively (Fig. 3B and C). In addition,
cAMP levels were correspondingly decreased by approximately
30% (Fig. 3D).
3.4. miR-181b promotes cell proliferation and reduces apoptosis by
repressing AC9 expression
The results above indicated that miR-181b might promote cell
proliferation by repressing the expression of AC9. To conﬁrm this
hypothesis, we ﬁrstly carried out MTT assays and colony formation
assays using cells transfected with the pSilencer/shR-AC9 plasmid.Fig. 3. miR-181b reduces the cellular level of cAMP by downregulating AC9 expression. (
incubated for 24 h after transfection. The concentration of cAMP was measured by cAMP
protein were measured by qRT-PCR and Western blot, respectively, and the concentrati
described in B–D. Cell viability was determined at 48, 72, and 96 h post-transfection b
formation assay (F). The representative pictures of ﬂowcytometry assay results were shCompared to the control group, cell viability of HeLa and C-33A
cells with low levels of AC9 increased approximately 1.3- to 1.5-
fold (Fig. 3E and F). The results of both ﬂowcytometry and TUNEL
assays showed that the knockdown of AC9 expression decreases
apoptosis in cervical cancer cells (Fig. 3G) (S2). Next, we con-
structed the pcDNA3/HA-AC9 vector, which was used to transcribe
AC9 mRNA without a 30UTR in cells. The relatively content of AC9
mRNA and its protein, as assayed by qRT-PCR and Western blot,
respectively, evaluated at the similar level between the group of
the cells cotransfected with pri-miR-181b and control group
(Fig. 4A and B). The concentrations of cAMP increased correspond-
ingly in both groups (S3). We also found that cell viability of the
HeLa and the C-33A cells promoted by miR-181b decreased by
approximately 50% and 30%, respectively, in cells overexpressing
AC9 (Fig. 4C and D). We performed the ﬂowcytometry and TUNEL
assays on the cells overexpressing AC9. The results showed that
AC9 expression increased apoptosis and rescued the suppression
of apoptosis caused by miR-181b in HeLa and C-33A cells
(Fig. 4E) (S4).
4. Discussion
miRNAs function as regulators of gene expression in various bio-
logical processes in cancer cells. In previous studies, miR-181b was
shown to play diverse roles in tumor cells [28,29]. The varying ef-
fects ofmiR-181b in different cell typesmainly depend on the targetA) HeLa and C-33A cells were transfected with pri-miR-181b or ASO-miR-181b and
assay. (B-D) HeLa and C-33A cells were transfected with shR-AC9. AC9 mRNA and
on of cAMP was measured by cAMP assay. (E–G) Experiments were carried out as
y the MTT assay (E). The cell growth capacity in vitro was assessed by the colony
own (G). (P < 0.05).
Fig. 4. Overexpression of AC9 counteracts the promotion of cell growth and the suppression of apoptosis caused by miR-181b in cervical cancer cells. (A–D) HeLa and C-33A
cells were transfected with pcDNA3/HA-AC9 or pcDNA3/HA accompanied with pri-miR-181b or no vector. AC9 mRNA and protein levels were detected by qRT-PCR (A) and
Western blot (B), respectively. GAPDH was used as an endogenous normalizer. Cell viability and growth capacity in vitro were determined by the MTT (C) and colony
formation assays (D). (E) Experiments were carried out as described in A–D. The representative pictures of ﬂowcytometry assay results were shown. (P < 0.05).
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sensitizes PDAC cells, gastric and lung cancer cells to chemotherapy
by targeting BCL-2 [30–32], while miR-181b facilitates tumor pro-
gression by suppressing TIMP3 expression in breast cancer and
HCC cells [33,34]. Previous study has showed that miR-181b may
stimulate HeLa cell growth and inhibit cell death [7]. Here, we
demonstrated that miR-181b promotes the proliferation of cervical
cancer cells using MTT and colony formation assays and inhibits
apoptosis in these cells using ﬂowcytometry and TUNEL assays.We identiﬁed adenylyl cyclase 9 (AC9), which produces cAMP, as
a potential target of miR-181b. Fluorescent reporter assays showed
the direct binding of miR-181b to the AC9 30UTR. qRT-PCR and
Western blot analyses showed that miR-181b negatively regulated
AC9 by reducing AC9 mRNA levels. In addition, functional assays
showed that the silencing of AC9 promoted cell growth, which is
consistent with the results of a previous study [19]. Importantly,
overexpression of AC9 can rescue the cellular effects induced by
miR-181b, further demonstrating that AC9 is a target for miR-181b.
130 L. Yang et al. / FEBS Letters 588 (2014) 124–130cAMP is an important modulator of apoptosis [26,27], and cAMP
analogs inhibit cell proliferation and promote apoptosis [35,36]. In
cancer cells, the analogs inhibit growth and differentiation by
differential modulation of protein kinase A (PKA) isozymes and
other factors. We show that miR-181b inhibits apoptosis by
targeting AC9, which synthesizes cAMP. However, cAMP acts as
both a pro-apoptotic and anti-apoptotic second messenger, and
different molecular mechanisms mediate the two effects [37,38].
In conclusion, we provide evidence that miR-181b restricts
cAMP production by targeting AC9 in cervical cancer cell lines. This
new mechanism for the regulation of miR-181b expression may
aid in the identiﬁcation of potential targets for therapy.
Acknowledgements
We thank our mentor and other teachers in our lab for critical
reading of the manuscript. This work was supported by the Na-
tional Natural Science Foundation of China (Nos. 31270818;
91029714; 31071191; 31101000), the Natural Science Foundation
of Tianjin (Nos. 12JCZDJC25100; 09JCZDJC17500).
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.febslet.2013.11.019.
References
[1] Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and
function. Cell 116, 281–297.
[2] Carroll, A.P., Tran, N., Tooney, P.A. and Cairns, M.J. (2012) Alternative mRNA
fates identiﬁed in microRNA-associated transcriptome analysis. BMC
Genomics 13, 561.
[3] Visone, R., Veronese, A., Rassenti, L.Z., Balatti, V., Pearl, D.K., Acunzo, M.,
Volinia, S., Taccioli, C., Kipps, T.J. and Croce, C.M. (2011) MiR-181b is a
biomarker of disease progression in chronic lymphocytic leukemia. Blood 118
(11), 3072–3079.
[4] Sun, X., Icli, B., Wara, A.K., Belkin, N., He, S., Kobzik, L., Hunninghake, G.M.,
Vera, M.P., Registry, M.I.C.U., Blackwell, T.S., Baron, R.M. and Feinberg, M.W.
(2012) MicroRNA-181b regulates NF-rB-mediated vascular inﬂammation. J.
Clin. Invest. 122 (6), 1973–1990.
[5] Chen, L., Yang, Q., Kong, W.Q., Liu, T., Liu, M., Li, X. and Tang, H. (2012)
MicroRNA-181b targets cAMP responds ive element binding protein 1 in
gastric adenocarcinomas. IUBMB Life 64 (7), 628–635.
[6] Visone, R., Veronese, A., Balatti, V. and Croce, C.M. (2012) MiR-181b: new
perspective to evaluate disease progression in chronic lymphocytic leukemia.
Oncotarget, 195–202.
[7] He, J., Zhang, J.F., Yi, C., Lv, Q., Xie, W.D., Li, J.N., Wan, G., Cui, K., Kung, H.F.,
Yang, J., Yang, B.B. and Zhang, Y. (2010) MiRNA-mediated functional changes
through co-regulating function related genes. PLoS One 5 (10), e13558.
[8] Bansal, N., Herzog, T.J., Shaw, R.E., Burke, W.M., Deutsch, I. and Wright, J.D.
(2009) Primary therapy for early-stage cervical cancer: radical hysterectomy
vs radiation. Am. J. Obstet. Gynecol. 201, e481–e489.
[9] Kosmas, C., Mylonakis, N., Tsakonas, G., Vorgias, G., Karvounis, N., Tsavaris, N.,
Daladimos, T., Kalinoglou, N., Malamos, N., Akrivos, T. and Karabelis, A. (2009)
Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed
and/or metastatic cervical cancer. Br. J. Cancer 101, 1059–1065.
[10] MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the
growth of HeLa cells.
[11] MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and
invasion by targeting CUL5.
[12] Defer, N., Best-Belpomme, M. and Hanoune, J. (2000) Tissue speciﬁcity and
physiological relevance of various isoforms of adenylyl cyclase. Am. J. Physiol.
Renal Physiol. 279 (3), F400–F416.
[13] Sunahara, R.K. and Taussig, R. (2002) Isoforms of mammalian adenylyl
cyclase: multiplicities of signaling. Mol. Interv. 2, 168–184.
[14] Houslay, M.D. and Adams, D.R. (2003) PDE4 cAMP phosphodiesterases:
modular enzymes that orchestrate signaling cross-talk, desensitization and
compartmentalization. Biochem. J. 370, 1–18.[15] Insel, P.A., Zhang, L., Murray, F., Yokouchi, H. and Zambon, A.C. (2012) Cyclic
AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta
Physiol. (Oxf.) 204 (2), 277–287.
[16] Reina, S., Ganzinelli, S., Sterin-Borda, L. and Borda, E. (2012) Pro-apoptotic
effect of anti-b(1)-adrenergic receptor antibodies in periodontitis patients. Int.
Immunopharmacol. 14 (4), 710–721.
[17] Jiang, Q., Bai, T., Shen, S., Li, L., Ding, H. and Wang, P. (2011) Increase of
cytosolic calcium induced by trichosanthin suppresses cAMP PKC levels
through the inhibition of adenylyl cyclase activity in HeLa cells. Mol. Biol. Rep.
38 (4), 2863–2868.
[18] Miller, R.L., Sandoval, P.C., Pisitkun, T., Knepper, M.A. and Hoffert, J.D. (2012)
Vasopressin inhibits apoptosis in renal collecting duct cells. Am. J. Physiol.
Renal Physiol. 304 (2), F177–F188.
[19] Han, J.H., Ahn, Y.H., Choi, K.Y. and Hong, S.H. (2009) Involvement of AMP-
activated protein kinase and p38 mitogen activated protein kinase in 8-Cl-
cAMP induced growth inhibition. J. Cell. Physiol. 218 (1), 104–112.
[20] Kim, S.N., Ahn, Y.H., Kim, S.G., Park, S.D., Cho-Chung, Y.S. and Hong, S.H. (2001)
8-Cl-cAMP induces cell cycle-speciﬁc apoptosis in human cancer cells. Int. J.
Cancer 93 (1), 33–41.
[21] Lucchi, S., Calebiro, D., de Filippis, T., Grassi, E.S., Borghi, M.O. and Persani, L.
(2011) 8-Chloro-Cyclic AMP and protein kinase A I-selective cyclic AMP
analogs inhibit cancer cell growth through different mechanisms. PLoS One 6
(6), e20785.
[22] Huang, B., Zhao, J., Lei, Z., Shen, S., Li, D., Shen, G.X., Zhang, G.M. and Feng, Z.H.
(2009) MiR-142-3p restricts cAMP production in CD4+ CD25 T cells and
CD4+ CD25+ TREG cells by AC9 mRNA. EMBO Rep. 10 (2), 180–185.
[23] Cumbay, M.G. and Watts, V.J. (2004) Novel regulatory properties of human
type 9 adenylate cyclase. J. Pharmacol. Exp. Ther. 310 (1), 108–115.
[24] Lerner, A., Kim, D.H. and Lee, R. (2000) The cAMP signaling pathway as a
therapeutic target in lymphoid malignancies. Leuk. Lymphoma 37 (1–2), 39–
51.
[25] Bøe, R., Gjertsen, B.T., Døskeland, S.O. and Vintermyr, O.K. (1995) 8-Chloro-
cAMP induces apoptotic cell death in a human mammary carcinoma cell
(MCF-7) line. Br. J. Cancer 72 (5), 1151–1159.
[26] Wang, P., Chen, L.L., Yan, H. and Li, J.C. (2009) Trichosanthin suppresses HeLa
cell proliferation through inhibition of the PKC/MAPK signaling pathway. Cell
Biol. Toxicol. 25 (5), 479–488.
[27] Robinson-White, A.J., Hsiao, H.P., Leitner, W.W., Greene, E., Bauer, A., Krett,
N.L., Nesterova, M. and Stratakis, C.A. (2008) Protein Kinase A-independent
inhibition of proliferation and induction of apoptosis in human thyroid cancer
cells by 8-Cl-adenosine. J. Clin. Endocrinol. Metab. 93 (3), 1020–1029.
[28] Shi, L., Cheng, Z., Zhang, J., Li, R., Zhao, P., et al. (2008) Hsa-mir-181a and hsa-
mir-181b function as tumor suppressors in human glioma cells. Brain Res.
1236, 185–193.
[29] Zhu, W., Shan, X., Wang, T., Shu, Y. and Liu, P. (2010) MiR-181b modulates
multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J.
Cancer 127, 2520–2529.
[30] Cai, B., An, Y., Lv, N., Chen, J., Tu, M., Sun, J., Wu, P., Wei, J., Jiang, K. and Miao, Y.
(2013) MiRNA-181b increases the sensitivity of pancreatic ductal
adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting
BCL-2. Oncol. Rep. 29 (5), 1769–1776.
[31] Dan Xia, Z., Wei, Z., Cheng, F., et al. (2012) MiR-181a/b signiﬁcantly enhances
drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple
anti-apoptosis genes. Carcinogenesis 33, 1294–1301.
[32] Zhu, W., Shan, X., Wang, T., Shu, Y. and Liu, P. (2010) MiR-181b modulates
multidrug resistance by targeting BCL2 in human cancer cell lines. Int. J.
Cancer 127, 2520–2529.
[33] Wang, B., Hsu, S.H., Majumder, S., et al. (2010) TGFbeta-mediated upregulation
of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3.
Oncogene 29, 1787–1797.
[34] Lu, Y., Roy, S., Nuovo, G., et al. (2011) Anti-microRNA-222 (anti-miR-222) and -
181B suppress growth of tamoxifen-resistant xenografts in mouse by
targeting TIMP3 protein and modulating mitogenic signal. J. Biol. Chem. 286,
42292–42302.
[35] Han, J.H., Ahn, Y.H., Choi, K.Y. and Hong, S.H. (2009) Involvement of AMP-
activated protein kinase and p38 mitogen activated protein kinase in 8 Cl
cAMP induced growth inhibition. J. Cell. Physiol. 218 (1), 104–112.
[36] Jiang, Q., Bai, T., Shen, S., Li, L., Ding, H. and Wang, P. (2010) Increase of
cytosolic calcium induced by trichosanthin suppresses cAMP PKC levels
through the inhibition of adenylyl cyclase activity in HeLa cells. Mol. Biol. Rep.
38 (4), 2863–2868.
[37] Grandoch, M., Roscioni, S.S. and Schmidt, M. (2010) The role of Epac proteins,
novel cAMP mediators, in the regulation of immune, lung and neuronal
function. Br. J. Pharmacol. 159, 265–284.
[38] Zhang, L., Zambon, A.C., Vranizan, K., Pothula, K., Conklin, B.R. and Insel, P.A.
(2008) Gene expression signatures of cAMP/protein kinase A (PKA)-promoted,
mitochondrial dependent apoptosis. Compara-tive analysis of wild-type and
cAMP-deathless S49 lymphoma cells. J. Biol. Chem. 283, 4304–4313.
